What is ARA 290
ARA 290 Cibinetide is a synthetic peptide compound belonging to erythropoietin derivatives (EPO-derived peptides), primarily exerting its biological effects by activating the innate repair receptor (IRR). Its CAS number is 1208243-50-8. With an optimized molecular structure, it exhibits anti-inflammatory, tissue-repair-promoting, and neuroprotective properties. Currently, it is primarily used in research and experimental fields, demonstrating particular prominence in studies of neurodegenerative diseases, diabetic complications, and tissue injury repair mechanisms.
ARA 290 selectively binds to IRR (composed of the erythropoietin receptor EPOR and the β-co-receptor CD131), activating downstream signaling pathways (such as JAK2/STAT3 and PI3K/AKT), inhibiting the release of inflammatory mediators (such as TNF-α and IL-6), while simultaneously promoting cell survival and angiogenesis. Compared to natural EPO, its structural modification avoids erythropoietic side effects, focusing more on tissue repair functions.
ARA 290 Benefits
Neuroscience Research: Validation of neuroprotective effects in models of Alzheimer’s disease, Parkinson’s disease, etc.;
Metabolic Disease Research: Evaluation of anti-fibrotic effects in diabetic peripheral neuropathy or nephropathy models;
Trauma Repair: Investigation of regenerative promotion in tissues such as myocardial ischemia and skin wounds.
ARA 290 Dosage
In clinical trials, ARA-290 is administered via subcutaneous injection at doses of 2–4 mg, typically once daily or several times weekly.
ARA 290 Side Effects
Mild headache or dizziness: Occasionally reported in clinical trials, usually transient.
Nausea or indigestion: Some patients experience mild gastrointestinal discomfort.
Injection site reactions: Redness, swelling, or irritation may occur after subcutaneous injection.
Reviews
There are no reviews yet.